Growth Metrics

Edwards Lifesciences (EW) Asset Writedowns and Impairment (2017 - 2026)

Edwards Lifesciences' quarterly Asset Writedowns and Impairment came in at $123.6 million in Q1 2026, down 15.86% quarter-over-quarter from $146.9 million in Q4 2025.

Edwards Lifesciences has reported Asset Writedowns and Impairment for 4 years, with the latest figure at $123.6 million in Q1 2026.

  • For the quarter ending Q1 2026, Asset Writedowns and Impairment changed N/A year-over-year to $123.6 million; the trailing twelve-month figure through Mar 2026 stood at $357.6 million (changed N/A YoY), and the FY2025 full-year result was $186.9 million, changed N/A from the prior year.
  • Asset Writedowns and Impairment for Q1 2026 stood at $123.6 million, down from $146.9 million in the prior quarter.
  • The five-year high for Asset Writedowns and Impairment was $146.9 million in Q4 2025, with the low at $40.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Zimmer Biomet Holdings 16.17 Bn 15.75 Bn 1.51 Bn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 123.60 Mn
Mar 31, 2026 123.60 Mn
Dec 31, 2025 146.90 Mn
Dec 31, 2025 146.90 Mn
Sep 30, 2025 40.00 Mn
Sep 30, 2025 40.00 Mn
Jun 30, 2025 47.10 Mn
Jun 30, 2025 47.10 Mn
Sep 30, 2019 26.90 Mn
Sep 30, 2019 26.90 Mn
Jun 30, 2019 46.20 Mn
Jun 30, 2019 46.20 Mn
Dec 31, 2017 -31.00 Mn
Dec 31, 2017 -31.00 Mn